Navigation Links
Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
Date:11/15/2007

Safety Analysis Shows Good Tolerance with No Serious Adverse Reactions

BERKELEY HEIGHTS, N.J., Nov. 15 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) released findings from the initial clinical dosing of G4544, the Company's proprietary small molecule that is intended as a treatment for diseases associated with accelerated bone loss. The Phase 1 study, which was conducted in normal volunteers, has shown good tolerance with oral bioavailability of the active ingredient, and an excellent safety profile without serious adverse reactions. The findings were released in an abstract published in the proceedings of the upcoming annual meeting of the American Society of Hematology.

G4544 is a new tablet formulation using delivery technology developed by Emisphere Technologies, Inc. that enables oral absorption of the active ingredient contained in Ganite(R) (gallium nitrate injection). Ganite(R) is marketed by Genta and approved in the U.S. for treatment of cancer-related hypercalcemia that is resistant to hydration. Low doses of the active ingredient in Ganite administered by intravenous or subcutaneous injections have shown clinical activity in a range of skeletal diseases, including hypercalcemia, bone metastasis (myeloma and breast cancer), Paget's disease, and osteoporosis.

The initial clinical trial was a Phase 1 study of escalating single doses of G4544 in 30 normal volunteers. The endpoints of the study were to determine safety and to assess pharmacokinetics and oral bioavailability. The drug was tested over a dosing range of the active ingredient from 30 to 150 mg, and no adverse effects attributable to G4544 were observed in this study. Initial analysis of plasma samples of low doses sh
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
3. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
4. Genta Incorporated Announces Third Quarter 2007 Financial Results
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
11. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  IGI Laboratories, Inc. (NYSE MKT: IG), ... company, announced its financial results for the second quarter ended ... , Total revenues of $6.5 million in the second ... quarter in 2013 , Total revenues of $13.3 million ... of 78% over the same period in 2013 , ...
(Date:7/24/2014)... ANGELES , July 24, 2014 Many new ... they can do to ensure that their practice will be ... purchase the basic supplies they use the most can make ... and many dentists have recently discovered that purchasing discount ... loss. According to successful dentists across ...
(Date:7/24/2014)... N.C. , July 24, 2014 ... has signed an Agreement with Kineticos, a ... consulting company. Kineticos will support LSI Medience in ... sepsis management, to demonstrate utility in clinical trials. ... shown potential utility in diagnosis of sepsis, prognosis ...
Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Dental Supplies Online is Key to Dental Success...Really! 2LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2
... 28, 2011  A 67-year-old man with Alzheimer,s disease is ... outside in near-freezing temperatures thanks to the quick action of ... wearable locator device. Robert Campbell was recovered ... He was located on Victory Boulevard, more than a mile ...
... LOS ANGELES, Feb. 28, 2011 InstaCare Corp. (OTC ... provider of direct to patient diabetes programs, a leading ... chronically ill, and a leading developer of revolutionary cell ... on Thursday, February 24, 2011, the Company filed a ...
Cached Medicine Technology:Staten Island Man Now Safe at Home Thanks to EmSeeQ® Locator Device 2Staten Island Man Now Safe at Home Thanks to EmSeeQ® Locator Device 3InstaCare Files Full Utility Patent for MD@Hand & MD@Work Technologies 2InstaCare Files Full Utility Patent for MD@Hand & MD@Work Technologies 3
(Date:7/25/2014)... Myers, FL (PRWEB) July 25, 2014 ... iPhones, iPods, and iPads. The app provides a tailored ... painful and potentially dangerous sunburns and skin damage. In ... the sights, sounds, and capabilities of iTanSmart. , ... describing the app as a ‘better organized’ and ‘great ...
(Date:7/25/2014)... As the category creator and world leader in healthy ... transform and improve individual lives worldwide through its exclusive and ... a successful Austin, Texas based "Xocai Activ Drink" author, is ... July to promote the up and coming mxicorp.com/company/igc Eric Worre ... has been a leader in the Network Marketing Profession for ...
(Date:7/24/2014)... July 25, 2014 iFitDress.com, a renowned ... new range of casual party dresses . According ... party gowns are now offered at discounted prices, up ... this morning until August 04. , Most of ... in the global market. They are popular for special ...
(Date:7/24/2014)... For rats bearing human breast tumors, exposure to dim ... breast cancer drug tamoxifen, according to data published in ... Association for Cancer Research. The negative effects of dim ... rats a melatonin supplement during the night. , "Resistance ... hormone receptor-positive breast cancer," said Steven M. Hill, PhD, ...
(Date:7/24/2014)... Ticket Down is a reliable source for cheap Manchester ... Authority Field on July 26th. For the past four years, the ... the best club teams from around the world to North America ... weeks after its completion, fans – new and old alike – ... in the world compete. Some of these players were already members ...
Breaking Medicine News(10 mins):Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3
... , CAMPBELL, Calif., Dec. 1 Last month on a prominent ... Stanford Sleep Disorders Clinic at Stanford University School of Medicine, recommended ... sleep plan for people trying to achieve a better night,s sleep ... for people when they are sleeping," said Dr. Pelayo. "There are ...
... Results of a large-scale clinical trial presented today at ... (RSNA) provide the first strong evidence of the benefit of ... at elevated risk for breast cancer. In addition, the study ... cancer. , "We found that annual screening with ultrasound in ...
... , , CHICAGO, Dec. 2 Targeted ... is a safe, reliable and cost-effective alternative to invasive biopsies ... two studies presented today at the annual meeting of the ... breast ultrasound, we can reduce the number of expensive and ...
... , SEATTLE, Dec. 2 ... today that Ruth Pettengell, M.D. of St. George,s Hospital, University ... trial will present new data on the pixantrone phase III ... Annual Meeting of the American Society of Hematology on Saturday, ...
... standard conservative therapy to a minimally invasive treatment called ... while both treatments help patients in the short run, ... two years later. Results of the study, the first ... meeting of the Radiological Society of North America (RSNA). ...
... ... , ... (Vocus) -- Omnetics Connector Corporation, the world leader in nano-miniature connectors, has announced the ... These are the smallest Mil-Quality circulars available. The threaded metal shell provides a ...
Cached Medicine News:Health News:Sleep Specialist Dr. Rafael Pelayo Recommends ASTI's Ecotones Duet Sleep Sound Machine 2Health News:Sleep Specialist Dr. Rafael Pelayo Recommends ASTI's Ecotones Duet Sleep Sound Machine 3Health News:Annual Screening With Breast Ultrasound or MRI Could Benefit Some Women 2Health News:Annual Screening With Breast Ultrasound or MRI Could Benefit Some Women 3Health News:Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty 2Health News:New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 2Health News:New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 3Health News:New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 4Health News:Outpatient disc treatment gives long-term back pain relief 2Health News:Omnetics Announces Newest Addition to Nano Circular Family 2
Provides 30% more illumination, high light output for true tissue. Wide-angle viewing lens, sealed system for pneumatic otoscopy....
... The Shandon Cryotome FE and FSE are ... Thermo Electron. The microtome is outside of ... cleaning, as well as faster temperature adjustment. ... operation. Complete temperature controls on the main ...
A standard, durable and reliable indirect....
Designed to retain the desired curve during oral intubation....
Medicine Products: